Intravitreal Bevacizumab for Diabetic Macular Edema Associated With Severe Capillary Loss: One-Year Results of a Pilot Study

American Journal of Ophthalmology

Volumn 147, Issue 6, 2009, Pages

  Bonini Filho, Marco ^a,b   Costa, Rogério A ^a,b   Calucci, Daniela ^a   Jorge, Rodrigo ^b   Melo Jr , Luiz A S ^a   Scott, Ingrid U ^c  

^a Hospital de Olhos de Araraquara   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; ARTICLE; CAPILLARY LOSS; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DIABETIC MACULAR EDEMA; DISEASE ASSOCIATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MALE; MICROANGIOPATHY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; VISUAL ACUITY;

EID: 67349141386     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2009.01.009     Document Type: Article

References (43)

1. Klein R., Klein B.E., Moss S.E., et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, IV: diabetic macular edema. Ophthalmology 91 (1984) 1464-1474
2. Early Treatment of Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: ETDRS Report No. 1. Arch Ophthalmol 103 (1985) 1796-1806
3. Early Treatment of Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: ETDRS Report No. 4. Int Ophthalmol Clin 27 (1987) 265-272
4. Early Treatment of Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS Report No. 9. Ophthalmology 98 (1991) 766-785
5. Early Treatment of Diabetic Retinopathy Study Research Group. Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Arch Ophthalmol 113 (1995) 1144-1155
6. Early Treatment of Diabetic Retinopathy Study Research Group. Classification of diabetic retinopathy from fluorescein angiograms: ETDRS Report No. 11. Ophthalmology 98 (1991) 807-822
7. Ticho U., and Patz A. The role of capillary perfusion in the management of diabetic macular edema. Am J Ophthalmol 76 (1973) 880-886
8. Adamis A.P., Miller J.W., Bernal M.T., et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118 (1994) 445-450
9. Dvorak H.F., Brown L.F., Detmar M., and Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146 (1995) 1029-1039
10. Murata T., Nakagawa K., Khali A., et al. The relation between expression of vascular endothelial growth factor and breakdown of the blood retinal barrier in diabetic rat retina. Lab Invest 74 (1996) 819-825
11. Amin R.H., Frank R.N., Kennedy A., et al. Vascular endothelium growth factor is present in glial cels of the retina and the optic nerve of human subjects with non-proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 38 (1997) 36-47
12. Funatsu H., Yamashita H., Noma H., et al. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 133 (2002) 70-77
13. Funatsu H., Yamashita H., Ikeda T., et al. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol 133 (2002) 537-543
14. Funatsu H., Yamashita H., Ikeda T., et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 110 (2003) 1690-1696
15. Funatsu H., Yamashita H., Sakata K., et al. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology 112 (2005) 806-816
16. Funatsu H., Yamashita H., Nakamura S., et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 113 (2006) 294-301
17. Nguyen Q.D., Tatlipinar S., Shah S.M., et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 142 (2006) 961-969
18. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., et al., VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004) 2805-2816
19. Cunningham Jr. E.T., Adamis A.P., Altaweel M., et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112 (2005) 1747-1757
20. Rosenfeld P.J., Moshfeghi A.A., and Puliafito C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36 (2005) 331-335
21. Rosenfeld P.J., Fung A.E., and Puliafito C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36 (2005) 336-339
22. Ferrara N., Hillan K.J., Gerber H.P., and Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 (2004) 391-400
23. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
24. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
25. Costa R.A., Calucci D., Skaf M., et al. Optical coherence tomography 3: Automatic delineation of the outer neural retinal boundary and its influence on retinal thickness measurements. Invest Ophthalmol Vis Sci 45 (2004) 2399-2406
26. Costa R.A., Skaf M., Melo Jr. L.A., et al. Retinal assessment using optical coherence tomography. Prog Retin Eye Res 25 (2006) 325-353
27. Sternberg Jr. P., Fitzke F., and Finkelstein D. Cyclic macular edema. Am J Ophthalmol 94 (1982) 664-669
28. Frank R.N., Schulz L., Abe K., and Iezzi R. Temporal variation in diabetic macular edema measured by optical coherence tomography. Ophthalmology 111 (2004) 211-217
29. Avery R.L., Pieramici D.J., Rabena M.D., et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113 (2006) 363-372
30. Iturralde D., Spaide R.F., Meyerle C.B., et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26 (2006) 279-284
31. Rich R.M., Rosenfeld P.J., Puliafito C.A., et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26 (2006) 495-511
32. Bashshur Z.F., Bazarbachi A., Schakal A., et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142 (2006) 1-9
33. Costa R.A., Jorge R., Calucci D., et al. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 47 (2006) 4569-4578
34. Costa R.A., Jorge R., Calucci D., et al. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 27 (2007) 141-149
35. Spaide R.F., and Fisher Y.L. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26 (2006) 275-278
36. Bakri S.J., Donaldson M.J., and Link T.P. Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab. Eye 20 (2006) 1474-1475
37. Chen E., and Park C.H. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 26 (2006) 699-700
38. Mason III J.O., Nixon P.A., and White M.F. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 142 (2006) 685-688
39. Avery R.L., Pearlman J., Pieramici D.J., et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113 (2006) 1695.e1-1695.e15
40. Haritoglou C., Kook D., Neubauer A., et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26 (2006) 999-1005
41. Jorge R., Costa R.A., Calucci D., et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBePe study). Retina 26 (2006) 1006-1013
42. Neubauer A.S., Kook D., Haritoglou C., et al. Bevacizumab and retinal ischemia. Ophthalmology 114 (2007) 2096
43. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 115 (2008) 1447-1449 1449.e1-10